Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Blood Advances|August 8, 2020
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R Wilson, Toby A Eyre, Nicolas Martinez-Calle, et al.
British Journal of Haematology|April 2, 2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalNicolás Martinez-Calle, Edward Poynton, Alia Alchawaf, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Leukemia & Lymphoma|December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaAhmad S Halwani, Carlos Panizo, Iris Isufi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa TrialLara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
American Journal of Hematology|March 3, 2023
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosingSuzanne O Arulogun, Duncan Brian, Harshita Goradia, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Pageof 5